![]() |
![]() |
My Amedeo
![]() ![]() ![]() |
![]() |
|||||||||
The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al. |
Prostate Cancer |
Free Subscription
1 BMC Cancer |
Retrieve available abstracts of this week’s articles:
HTML format |
Single Articles |
AMEDEO Prostate Cancer is free of charge.
Protocol for CHAMPION study: a prospective study of maximal-cytoreductive
therapies for patients with de novo metastatic hormone-sensitive prostate cancer
who achieve oligopersistent metastases during systemic treatment with apalutamide
plus androgen
BMC Cancer. 2024;24:643.
PubMed
Abstract available
Clinical evaluation of the efficacy of limbus artificial intelligence software to
augment contouring for prostate and nodes radiotherapy.
Br J Radiol. 2024;97:1125-1131.
PubMed
Abstract available
Accuracy of Magnetic Resonance Imaging-Ultrasound Fusion-Guided and Systematic
Biopsy of the Prostate.
Br J Radiol. 2024 Apr 16:tqae080. doi: 10.1093.
PubMed
Abstract available
Race has no impact on prostate cancer-specific mortality, when comparing patients
with similar risk of other-cause mortality: An analysis of a population-based
cohort.
Cancer. 2024 May 28. doi: 10.1002/cncr.35386.
PubMed
Abstract available
Decreased prostate MRI cancer detection rate due to moderate to severe
susceptibility artifacts from hip prosthesis.
Eur Radiol. 2024;34:3387-3399.
PubMed
Abstract available
Re: Michael Baboudjian, Romain Diamand, Alessandro Uleri, et al. Does Overgrading
on Targeted Biopsy of Magnetic Resonance Imaging-visible Lesions in Prostate
Cancer Lead to Overtreatment? Eur Urol. In press.
https://doi.org/10.1016/j.eururo.2024.02.0
Eur Urol. 2024 May 25:S0302-2838(24)02385-6. doi: 10.1016/j.eururo.2024.
PubMed
Reply to Hein V. Stroomberg, Klaus Brasso, and Andreas Roder's Letter to the
Editor re: Michael Baboudjian, Romain Diamand, Alessandro Uleri, et al. Does
Overgrading on Targeted Biopsy of Magnetic Resonance Imaging-visible Lesions in
Prostate Cancer L
Eur Urol. 2024 May 24:S0302-2838(24)02387-X. doi: 10.1016/j.eururo.2024.
PubMed
Reply to Andrew J. Vickers' Letter to the Editor re: Michael Baboudjian, Romain
Diamand, Alessandro Uleri, et al. Does Overgrading on Targeted Biopsy of Magnetic
Resonance Imaging-visible Lesions in Prostate Cancer Lead to Overtreatment? Eur
Urol. In
Eur Urol. 2024 May 24:S0302-2838(24)02386-8. doi: 10.1016/j.eururo.2024.
PubMed
Development of a Visually Calculated SUV(mean) (HIT Score) on Screening PSMA
PET/CT to Predict Treatment Response to (177)Lu-PSMA Therapy: Comparison with
Quantitative SUV(mean) and Patient Outcomes.
J Nucl Med. 2024 Apr 18:jnumed.123.267014. doi: 10.2967/jnumed.123.267014.
PubMed
Abstract available
Long-Term Outcomes in Patients Using Protocol-Directed Active Surveillance for
Prostate Cancer.
JAMA. 2024 May 30. doi: 10.1001/jama.2024.6695.
PubMed
Abstract available
Rediscovering citrate as a biomarker for prostate cancer.
Nat Rev Urol. 2024 May 29. doi: 10.1038/s41585-024-00899.
PubMed
Knowledge and practices regarding prostate cancer screening in Spanish men: The
importance of personal and clinical characteristics (PROSHADE study).
PLoS One. 2024;19:e0303203.
PubMed
Abstract available
Serum (-2)proPSA/freePSAratio, (-2)proPSA/freePSA density, prostate health index,
and prostate health index density as clues to reveal postoperative clinically
significant prostate cancer in men with prostate-specific antigen 2-10 ng/mL.
Prostate. 2024 May 26. doi: 10.1002/pros.24752.
PubMed
Abstract available
Impact of comorbidities on prostate cancer-specific mortality: A population-based
cohort study.
Prostate. 2024 May 26. doi: 10.1002/pros.24750.
PubMed
Abstract available
External validation of the Memorial Sloan Kettering Cancer Center preoperative
nomogram predicting lymph node invasion in a cohort of high-grade prostate cancer
patients.
Prostate. 2024 May 27. doi: 10.1002/pros.24742.
PubMed
Abstract available
Impact of PSA nadir, PSA response and time to PSA nadir on overall survival in
real-world setting of metastatic hormone-sensitive prostate cancer patients.
Prostate. 2024 May 29. doi: 10.1002/pros.24754.
PubMed
Abstract available
Perioperative rates of incidental prostate cancer after aquablation and holmium
laser enucleation of the prostate (HoLEP).
Urol Int. 2024 May 27. doi: 10.1159/000539014.
PubMed
Abstract available
Thank you for your interest in scientific medicine.